JP2018510189A - アクリジニウム臭化物の製造方法 - Google Patents

アクリジニウム臭化物の製造方法 Download PDF

Info

Publication number
JP2018510189A
JP2018510189A JP2017551330A JP2017551330A JP2018510189A JP 2018510189 A JP2018510189 A JP 2018510189A JP 2017551330 A JP2017551330 A JP 2017551330A JP 2017551330 A JP2017551330 A JP 2017551330A JP 2018510189 A JP2018510189 A JP 2018510189A
Authority
JP
Japan
Prior art keywords
bromide
acridinium
mixture
solvent
acridinium bromide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017551330A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510189A5 (enExample
Inventor
メンデス，ジタ
カセラ，コンスタンサ
カリナ コンスタンティノ，アナ
カリナ コンスタンティノ，アナ
サントス，ブルノ
Original Assignee
ホビオネ サイエンティア リミテッド
ホビオネ サイエンティア リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ホビオネ サイエンティア リミテッド, ホビオネ サイエンティア リミテッド filed Critical ホビオネ サイエンティア リミテッド
Publication of JP2018510189A publication Critical patent/JP2018510189A/ja
Publication of JP2018510189A5 publication Critical patent/JP2018510189A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0018—Evaporation of components of the mixture to be separated
    • B01D9/0027—Evaporation of components of the mixture to be separated by means of conveying fluid, e.g. spray-crystallisation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Catalysts (AREA)
JP2017551330A 2015-03-30 2016-03-30 アクリジニウム臭化物の製造方法 Pending JP2018510189A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT10837015A PT108370B (pt) 2015-03-30 2015-03-30 Processo de preparação de brometo de aclidínio
PT108370 2015-03-30
PCT/GB2016/050888 WO2016156836A1 (en) 2015-03-30 2016-03-30 Process for the preparation of aclidinium bromide

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020097781A Division JP2020143160A (ja) 2015-03-30 2020-06-04 アクリジニウム臭化物の製造方法
JP2020185042A Division JP7124035B2 (ja) 2015-03-30 2020-11-05 アクリジニウム臭化物の製造方法

Publications (2)

Publication Number Publication Date
JP2018510189A true JP2018510189A (ja) 2018-04-12
JP2018510189A5 JP2018510189A5 (enExample) 2019-04-18

Family

ID=55806548

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017551330A Pending JP2018510189A (ja) 2015-03-30 2016-03-30 アクリジニウム臭化物の製造方法
JP2020097781A Pending JP2020143160A (ja) 2015-03-30 2020-06-04 アクリジニウム臭化物の製造方法
JP2020185042A Active JP7124035B2 (ja) 2015-03-30 2020-11-05 アクリジニウム臭化物の製造方法
JP2022128244A Pending JP2022160667A (ja) 2015-03-30 2022-08-10 アクリジニウム臭化物の製造方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020097781A Pending JP2020143160A (ja) 2015-03-30 2020-06-04 アクリジニウム臭化物の製造方法
JP2020185042A Active JP7124035B2 (ja) 2015-03-30 2020-11-05 アクリジニウム臭化物の製造方法
JP2022128244A Pending JP2022160667A (ja) 2015-03-30 2022-08-10 アクリジニウム臭化物の製造方法

Country Status (9)

Country Link
US (2) US10087177B2 (enExample)
EP (1) EP3277679A1 (enExample)
JP (4) JP2018510189A (enExample)
CN (1) CN108112252B (enExample)
AU (1) AU2016240289B2 (enExample)
CA (2) CA3165243A1 (enExample)
IL (1) IL254712A0 (enExample)
PT (1) PT108370B (enExample)
WO (1) WO2016156836A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT108370B (pt) 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
CN108586450B (zh) * 2017-12-15 2021-02-19 上海方予健康医药科技有限公司 一种胆碱m受体抗结剂的重结晶纯化方法
PT115583B (pt) * 2019-06-17 2022-05-02 Hovione Farm S A Processo contínuo para a preparação de medicamentos anticolinérgicos
CN114890997A (zh) * 2022-04-20 2022-08-12 江苏联环药业股份有限公司 一种抗胆碱能药物噻格溴铵的制备工艺

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504368A (ja) * 1999-07-14 2003-02-04 アルミラル・プロデスフアルマ・エス・エイ キヌクリジン誘導体およびそれらのムスカリンｍ３レセプターリガンドとしての使用
JP2003519698A (ja) * 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ，インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
JP2007500151A (ja) * 2003-07-29 2007-01-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベータ受容体刺激薬及び抗コリン薬を含む吸入用医薬
JP2009522278A (ja) * 2005-12-28 2009-06-11 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
JP2009544591A (ja) * 2006-07-21 2009-12-17 アルミラル・ソシエダッド・アノニマ 臭化３（ｒ）−（２−ヒドロキシ−２，２−ジチエン−２−イルアセトキシ）−１−（３−フェノキシプロピル）−１−アゾニアビシクロ［２．２．２］オクタンの製造方法
JP2012136534A (ja) * 2000-10-03 2012-07-19 F Hoffmann La Roche Ag 細胞周期阻害物質の非晶質形態
WO2015062560A1 (en) * 2013-10-29 2015-05-07 Zentiva, K.S. An industrially applicable process for preparing high purity aclidinium bromide
WO2015071824A1 (en) * 2013-11-13 2015-05-21 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for the preparation of aclidinium bromide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
EP3401316B1 (en) * 2012-08-15 2021-08-04 Glaxo Group Limited Chemical process
PT108370B (pt) 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504368A (ja) * 1999-07-14 2003-02-04 アルミラル・プロデスフアルマ・エス・エイ キヌクリジン誘導体およびそれらのムスカリンｍ３レセプターリガンドとしての使用
JP2003519698A (ja) * 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ，インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
JP2012136534A (ja) * 2000-10-03 2012-07-19 F Hoffmann La Roche Ag 細胞周期阻害物質の非晶質形態
JP2007500151A (ja) * 2003-07-29 2007-01-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベータ受容体刺激薬及び抗コリン薬を含む吸入用医薬
JP2009522278A (ja) * 2005-12-28 2009-06-11 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
JP2009544591A (ja) * 2006-07-21 2009-12-17 アルミラル・ソシエダッド・アノニマ 臭化３（ｒ）−（２−ヒドロキシ−２，２−ジチエン−２−イルアセトキシ）−１−（３−フェノキシプロピル）−１−アゾニアビシクロ［２．２．２］オクタンの製造方法
WO2015062560A1 (en) * 2013-10-29 2015-05-07 Zentiva, K.S. An industrially applicable process for preparing high purity aclidinium bromide
WO2015071824A1 (en) * 2013-11-13 2015-05-21 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for the preparation of aclidinium bromide

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"医薬品の残留溶媒ガイドラインについて", 医薬審第３０７号, JPN6010003282, 1998, ISSN: 0004169052 *
"新医薬品の規格及び試験方法の設定について", 医薬審発第５６８号, JPN6010021254, 2001, ISSN: 0004169047 *
BYRN S: "PHARMACEUTICAL SOLIDS: A STRATEGIC APPROACH TO REGULATORY CONSIDERATIONS", PHARMACEUTICAL RESEARCH, vol. V12 N7, JPN5013009960, 1 July 1995 (1995-07-01), US, pages 945 - 954, ISSN: 0004169051 *
MARIA PRAT; ET AL: "DISCOVERY OF NOVEL QUATERNARY AMMONIUM DERIVATIVES OF (3R)-QUINUCLIDINOL ESTERS AS POTENT 以下備考", JOURNAL OF MEDICINAL CHEMISTRY, vol. VOL:52, NR:16, JPN5018001422, 27 August 2009 (2009-08-27), pages 5076 - 5092, ISSN: 0004169045 *
大島寛: "結晶多形・擬多形の析出挙動と制御", PHARM STAGE, vol. 6, no. 10, JPN6011001457, 15 January 2007 (2007-01-15), pages 48 - 53, ISSN: 0004169048 *
山野光久: "医薬品のプロセス研究における結晶多形現象への取り組み", 有機合成化学協会誌, vol. 65, no. 9, JPN6010003277, 1 September 2007 (2007-09-01), pages 907 - 69, ISSN: 0004169050 *
川口洋子ら: "医薬品と結晶多形", 生活工学研究, vol. 4, no. 2, JPN6014015069, 2002, pages 310 - 317, ISSN: 0004169046 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0004169049 *

Also Published As

Publication number Publication date
US20180105517A1 (en) 2018-04-19
US10087177B2 (en) 2018-10-02
AU2016240289B2 (en) 2020-08-27
JP2020143160A (ja) 2020-09-10
PT108370B (pt) 2018-10-25
US10590124B2 (en) 2020-03-17
IL254712A0 (en) 2017-11-30
CN108112252A (zh) 2018-06-01
AU2016240289A1 (en) 2017-10-19
PT108370A (pt) 2016-09-30
JP7124035B2 (ja) 2022-08-23
EP3277679A1 (en) 2018-02-07
CA2980665A1 (en) 2016-10-06
US20180362523A1 (en) 2018-12-20
JP2021020965A (ja) 2021-02-18
JP2022160667A (ja) 2022-10-19
CA3165243A1 (en) 2016-10-06
WO2016156836A1 (en) 2016-10-06
CN108112252B (zh) 2020-11-24

Similar Documents

Publication Publication Date Title
JP7124035B2 (ja) アクリジニウム臭化物の製造方法
KR101290893B1 (ko) 피롤리디늄 염의 제조 방법
JP6118826B2 (ja) 臭化チオトロピウムの調製方法
JP5642766B2 (ja) アデフォビルジピボキシルの新規結晶形及びその製造方法
JP2018510189A5 (enExample)
EP1968978A2 (en) Forms of dolasetron mesylate and processes for their preparation
JP2014201592A (ja) 臭化チオトロピウムの結晶形態
CN108586450B (zh) 一种胆碱m受体抗结剂的重结晶纯化方法
JP2018531249A (ja) ホスネツピタントの結晶形
JP2018531249A6 (ja) ホスネツピタントの結晶形
JP2012500268A (ja) ７−クロロ−Ｎ，Ｎ，５−トリメチル−４−オキソ−３−フェニル−３，５−ジヒドロ−４Ｈ−ピリダジノ［４，５−ｂ］インドール−１−アセトアミドの多形体を製造するための方法
WO2012096632A1 (en) New addition salts of ziprasidone, a process for the preparation thereof and use thereof in therapy

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20171129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190308

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200604

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200707